Cardiology Pharmacist. Melanie Madorsky, PharmD, BCPS TSHP Annual Meeting April 7, 2018
|
|
|
- Joseph Hoover
- 6 years ago
- Views:
Transcription
1 Cardiology Pharmacist Melanie Madorsky, PharmD, BCPS TSHP Annual Meeting April 7, 2018
2 Objectives Explain the daily responsibilities of the Cardiology Pharmacist Identify the importance of optimizing medication therapy in patients with cardiovascular disease Describe the role the Cardiology Pharmacist has in optimizing medication therapy in patients with cardiovascular disease
3 Cardiology Pharmacy Practice Focuses on the pharmaceutical care of cardiovascular patients Variety of settings: Inpatient Coronary care units (CCU) Cardiovascular intensive care units (CVICU) Cardiology step-down units Medical intensive care units (MICU) Surgical intensive care units (SICU) Emergency departments (ED) Outpatient Dyslipidemia Heart failure Hypertension Anticoagulation Cardiac transplant Arrhythmias Menighan TE, Maddux MS, Abramowitz PW. Feb 6, 2012.
4 A Day in the Life Cardiology Pharmacist Clinical Services Daily Responsibilities Education Committee Involvement Research
5 A Day in the Life Cardiology Pharmacist Daily Responsibilities Clinical Services Education Committee Involvement Member of the interprofessional health care team Pharmacy consults Core measures Emergency code response Research
6 Role in Multidisciplinary Team Disease state management Improving guideline adherence Pharmacokinetic drug monitoring Dosage adjustments based on patient factors Appropriate titration of medications Identifying and avoiding contraindicated drugs Identifying drugdisease interactions Identifying effective medication substitutions Identifying costeffective medications Adverse drug reaction prevention and intervention Improving communication in transitions of care Menighan TE, Maddux MS, Abramowitz PW. Feb 6, 2012.
7 Pharmacy Medication Consults Allows pharmacists to optimize medication therapy through P&T approved policies and procedures Consults Warfarin dosing/anticoagulation Vancomycin/Aminoglycosides IV to PO conversions Renal adjustments
8 ACE = Angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; ARNI = angiotensin receptor-neprilysin inhibitor Joint Commission Core Measures Cardiology pharmacist helps to improve adherence to Joint Commission Core Measures and best practice standards Heart Failure Acute Myocardial Infarction Cardiac Surgery ACE/ARB/ARNI ASA/P2Y12 Inhibitor Pre-Op Beta Blocker Beta Blocker Statin Antiplatelet Beta Blocker Statin ACE/ARB Beta Blocker
9 Emergency Code Response Optimize medication therapy Code Blue Response Rapid Response Stroke Alert Code STEMI
10 A Day in the Life Cardiology Pharmacist Clinical Services Daily Responsibilities Education Committee Involvement Health care professionals Patients Research
11 Health Care Professional Education Provide pharmacotherapy-related education about cardiovascular medications to: Pharmacists Pharmacy residents Student pharmacists Medical students Medical residents Physicians Nurses Topic discussions/inservices Grand rounds Continuing education College of pharmacy involvement
12 Patient Education Improve patient knowledge of cardiovascular medications, adverse effects, and disease states through education New Medications Anticoagulation Warfarin Direct Acting Oral Anticoagulants Anti-arrhythmics Heart Failure Acute Myocardial Infarction Discontinued Medications Goal to improve understanding and adherence and reduce hospitalizations and adverse events
13 A Day in the Life Cardiology Pharmacist Clinical Services Daily Responsibilities Education Committee Involvement Hospital National Research
14 Committee Involvement Hospital Committees (examples) Pharmacy and Therapeutics Committee STEMI Multidisciplinary Committee Cardiothoracic Surgery Team Committee Congestive Heart Failure Committee Code Blue Committee National Organizations (examples) American Society of Health-System Pharmacists (ASHP) American College of Clinical Pharmacy (ACCP) ACCP Cardiology Practice and Research Network American College of Cardiology (ACC)
15 A Day in the Life Cardiology Pharmacist Clinical Services Daily Responsibilities Education Committee Involvement Research Quality improvement projects Clinical studies
16 Question 1 Which of the following is a daily responsibility for a cardiology pharmacist? A. Round with the interdisciplinary team B. Provide patient education C. Answer drug information questions D. All of the above
17 Question 1 Which of the following is a daily responsibility for a cardiology pharmacist? A. Round with the interdisciplinary team B. Provide patient education C. Answer drug information questions D. All of the above
18 Question 2 True or False: When counseling a newly diagnosed heart failure patient on their medications, it is NOT important to discuss the indication for these new medications.
19 Question 2 True or False: When counseling a newly diagnosed heart failure patient on their medications, it is NOT important to discuss the indication for these new medications.
20 Question 3 The cardiology pharmacist can improve patient care by: A. Advising the patient on how to take their medications B. Evaluating the safety of patient medications C. Providing recommendations to optimize medication therapy D. All of the above
21 Question 3 The cardiology pharmacist can improve patient care by: A. Advising the patient on how to take their medications B. Evaluating the safety of patient medications C. Providing recommendations to optimize medication therapy D. All of the above
22 Cardiology Pharmacist Melanie Madorsky, PharmD, BCPS TSHP Annual Meeting April 7, 2018
Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
The University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
Heart Failure Clinic: A Multidisciplinary Approach
Heart Failure Clinic: A Multidisciplinary Approach Deborah Caraballo, RPh, PharmD, PhC, BCPS-Cardiology Wilson Cardiology Lecture September 16 th, 2017 ALLPPT.com _ Free PowerPoint Templates, Diagrams
What s at the Heart of the Matter?
What s at the Heart of the Matter? Inpatient Pharmacy Services for Heart Failure Patients Jason Williamson, PharmD, BCPS Clinical Pharmacy Manager, PGY1 Pharmacy Residency Director Genesys Regional Medical
Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
Drs. Rottman, Salloum, Campbell, Muldowney, Hong, Bagai, Kronenberg
Rotation: or: Faculty: Coronary Care Unit (CVICU) Dr. Jeff Rottman Drs. Rottman, Salloum, Campbell, Muldowney, Hong, Bagai, Kronenberg Duty Hours: Mon Fri, 7 AM to 7 PM, weekend call shared with consult
Summary of Research and Writing Activities In Cardiovascular Disease
Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension
Medical Apps for Cardiology Uses. There s an App for That!
Medical Apps for Cardiology Uses There s an App for That! Audience Participation Question #1 1. ASCVD Risk App What is the predicted 10 year CV event rate for a 57 y/o black male patient with treated
THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE: 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40%
Quality ID #118 (NQF 0066): Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction
Long-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
Quality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic
Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic June Chen 1, Charlotte Galenza 1, Justin Ezekowitz 2,3,
2012 Core Measures. Acute Myocardial Infarction (AMI)
2012 Core Measures Acute Myocardial Infarction (AMI) Aspirin at Arrival Aspirin Prescribed at Discharge Angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for left ventricular
Practice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
UH Case Medical Center Adult Inpatient Telemetry Admission, Transfer and Discharge Guidelines
UH Case Medical Center Adult Inpatient Telemetry Admission, Transfer and Discharge Guidelines STATEMENT OF PURPOSE: To facilitate appropriate geo-location placement of patients who require telemetry monitoring
Quality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
ARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists
Entresto: An Overview for Pharmacists David Comshaw, PharmD Candidate 2019 1 Gyen Musgrave, PharmD Candidate 2019 1 Suzanne Surowiec, PharmD, BCACP 1 Jason Guy, PharmD 1 1 University of Findlay College
Consensus Core Set: Cardiovascular Measures Version 1.0
Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized
Condition/Procedure Measure Compliance Criteria Reference Attribution Method
Premium Specialty: Cardiology Credentialed Specialties include: Cardiac Diagnostic, Cardiology, Cardiovascular Disease, Clinical Cardiac Electrophysiology, and Interventional Cardiology This document is
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
Long-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
Quality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
Initiating New Medications in the Management of Heart Failure
Initiating New Medications in the Management of Heart Failure Sandra Oliver-McNeil DNP, MSN, ACNP-BC, CHFN Associate Professor (Clinical) Wayne State University College of Nursing Objectives The participant
Content Outline Cardiology Pharmacy Exam June 2017
Content Outline Cardiology Pharmacy Exam June 2017 The following domains, tasks and knowledge statements were delineated by the BPS Cardiology Practice Analysis Taskforce and validated through a role delineation
The Future of Cardiac Care: Managing Our Patients Together
The Future of Cardiac Care: Managing Our Patients Together Charles R. Caldwell, MD, FACC Disclosures: iheartdoc,inc. Telemedicine 1 MACRA Medicare Access and CHIP Reauthorization Act of 2015 Repealed the
Acute Coronary Syndrome- The Role of the ACS Clinic in Providing Best Practice Care
Acute Coronary Syndrome- The Role of the ACS Clinic in Providing Best Practice Care Deborah Pora MSN, ANP-C, RCIS Objectives Review the latest treatment guidelines for adults with acute coronary syndrome
CARDIAC REHABILITATION PROGRAMME:- MEDICATION
CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to
PREVENTIVE AND REHABILITATIVE MANAGEMENT OF ACUTE CORONARY SYNDROMES (NSTEMI, STEMI, PCI)
PREVENTIVE AND REHABILITATIVE MANAGEMENT OF ACUTE CORONARY SYNDROMES (NSTEMI, STEMI, PCI) Dato Dr. Balachandran Kandasamy Institut Jantung Negara 12 th November 2016 KEY MESSAGES 1. Initiate a long-term
TSHP 2014 Annual Seminar 1
Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical
Summary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy. anticoagulation can be continued,
Experts Answering Your Questions Anticoagulating a high-risk cardiac patient 1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy for minor surgical
Educational Goals and Objectives for Rotations on: Cardio Inpatient
Educational Goals and Objectives for Rotations on: Cardio Inpatient Residents will rotate through cardiology inpatient rotations to: Develop skills to evaluate and manage patients with diseases of the
The New Priority: Decreasing Readmissions after Cardiothoracic Surgery: How Do We Get There?
The New Priority: Decreasing Readmissions after Cardiothoracic Surgery: How Do We Get There? Michael Zhen-Yu Tong, MD, MBA Department of Cardiothoracic Surgery Cleveland Clinic No Disclosures Plan Background
Updates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
Know the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium
Know the Quality of our Care at Every Step Kansas City ACS Summit BI-State Cardiovascular Education Consortium Welcome to the Kansas City ACS Summit Objectives: Follow the flow and care of an ACS patient
Pharmacogenomics with Clopidogrel: Does One Size Fit All?
Pharmacogenomics with Clopidogrel: Does One Size Fit All? Leah A. Sabato, PharmD PGY-1 Pharmacy Practice Resident UC Health - University of Cincinnati Medical Center leah.sabato@uchealth.com April 2015
LAC-USC Cardiology Consult Service
LAC-USC Cardiology Consult Service RESIDENT ORIENTATION First Day of Rotation: Report to 1 st day at LAC + USC Hospital 4 th floor Cardiology units Page Fellow day before rotation for more information
CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016
CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 WHAT IS AN EPISODE OF CARE? An episode of care is a grouping of a patient s health care claims for a unique
The Changing Epidemiology of Acute Coronary Syndromes: Implications for practice: Dr. Sonia Anand, McMaster University
The Changing Epidemiology of Acute Coronary Syndromes: Implications for practice: Dr. Sonia Anand, McMaster University Expert Opinions CCS Vancouver, BC October 23, 2011 Overview of ACS Epidemiology: Global
1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
The ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
National Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
New Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior
Acute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
THE BRIDGE-ACS TRIAL
A Multifaceted Intervention to Narrow the Evidence-Based Gap in the Treatment of Acute Coronary Syndromes: THE BRIDGE-ACS TRIAL Presenter: Otavio Berwanger (MD; PhD) on Behalf of the BRIDGE-ACS Steering
Multidisciplinary Geriatric Trauma Care Guideline
Multidisciplinary Geriatric Trauma Care Background Traumatic injury in the geriatric population is increasing in prevalence and is associated with higher mortality and complication rates comparted to younger
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management
The P&T Committee Lisinopril (Qbrelis )
Situation Background Assessment The P&T Committee Lisinopril (Qbrelis ) Qbrelis, 1 mg/ml lisinopril oral solution, has recently become an FDA- approved formulation. Current practice at UK Chandler Medical
GET WITH THE GUIDELINES- PAST AND FUTURE
GET WITH THE GUIDELINES- PAST AND FUTURE Amy Graham, RN, BS, CEN, NREMT-P Director, Quality & Systems Improvement Kentucky and Southwest Ohio American Heart Association 1 DISCLOSURE SLIDE I AM THE QUALITY
Clinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
Supplementary Online Content
Supplementary Online Content Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA 2 DS 2 -VASc Score. JAMA Netw
HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
HealthLine. Focus on Heart Failure Part 2: Treatment Considerations
December 2017 THE OMNICARE HealthLine Focus on Heart Failure Part 2: Treatment Considerations Several studies have demonstrated that a lack of using guideline-directed therapy is associated with increased
What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr)
What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE Marc Ferrini (Lyon Fr) Palermo (I) 1 04 2017 Consulting Fees, Honoraria: BAYER PHARMA BOEHRINGER INGELHEIM BRISTOL MEYERS
HEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
AMI Talking Points. Provide appropriate treatment to Acute MI patients with these core measures:
AMI Provide appropriate treatment to Acute MI patients with these core measures: Aspirin received within 24 hours of arrival or contraindication documented Primary PCI Received Within 90 Minutes of Hospital
Supplementary Online Content
Supplementary Online Content Hayes J, Jackson JL, McNutt GM, Hertz BJ, Ryan JJ, Pawlikowski SA. Association between physician time-unlimited vs time-limited internal medicine board certification and ambulatory
The CSAC will review recommendations from the Cardiovascular 2015 project during its January 12, 2016 conference call.
TO: FR: RE: Consensus Standards Approval Committee (CSAC) Melissa Marinelarena, Leslie Vicale, Donna Herring Cardiovascular 2015 Member Voting Results DA: January 12, 2016 The CSAC will review recommendations
STEMI, Non-STEMI, Chest Pain?
Minnesota Chest Pain / Acute Coronary Syndrome Tool-Kit Patient with Chest Pain Or Potential Acute Coronary Syndrome STEMI, n-stemi, Chest Pain? Follow MN STEMI Guideline Follow MN n-stemi Guideline Follow
Eplerenon Medical Valley + Eplerenon Stada
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Heart failure is a complex syndrome, clinically characterized by signs and symptoms secondary to abnormal cardiac function. It
Aspirin Dose for Cardiovascular Indications
PL Detail-Document #280901 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER September 2012 Aspirin Dose
Acute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION CORPORATION DATE: 17-04-2015, VERSION 2 VI.2 Elements for
Critical Care PGY2 Core Rotation Preceptor Biography
Critical Care PGY2 Core Rotation Preceptor Biography Rima Bouajram, PharmD rima.bouajram@ucsf.edu PharmD, University of Texas at Austin, 2013 PGY1 General Practice, UC San Diego Health System, 2014; PGY2
NATIONAL QUALITY FORUM
Cardiovascular and Diabetes Task Force Summary of In-Person Meeting #2 An in-person meeting of the Measure Applications Partnership (MAP) Cardiovascular and Diabetes Task Force was held on Tuesday, July
Hypokalemia in Acute Coronary Syndromes and Acute Decompensated Heart Failure
Hypokalemia in Acute Coronary Syndromes and Acute Decompensated Heart Failure Joseph S. Van Tuyl, Pharm.D. PGY1 Pharmacy Resident The University of Oklahoma College of Pharmacy April 4, 2014 Disclosures
Welcome to Acute Care Preceptors Conference October 27 th 2009
Welcome to Acute Care Preceptors Conference October 27 th 2009 Agenda Welcome Follow up from last conference Online training opportunities via SSPPS website Therapeutics Best practice in acute care series
Guidelines for the Prescribing of Sacubitril / Valsartan
Hull & East Riding Prescribing Committee Guidelines for the Prescribing of Sacubitril / Valsartan 1. BACKGROUND Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor, including both a neprilysin
Heart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice
CONTINUING EDUCATION Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice GOAL To provide participants with current information about current blood pressure goals and effective
Jan Feb Mar Apr May Jun Jul Aug Sep X X X X X X X. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov X X X X X X X X X X X X X
Primary Prevention Breast Cancer Prevention Member: Mammography reminder letters to female members ages 51.5-74 who are overdue to get a mammogram Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Providers:
Saudi Heart Failure Guidelines. Waleed AlHabeeb, MD, MHA Consultant Heart Failure Cardiologist President of the Saudi Heart Failure Group
Saudi Heart Failure Guidelines Waleed AlHabeeb, MD, MHA Consultant Heart Failure Cardiologist President of the Saudi Heart Failure Group Heart Failure Expert committee The Heart Failure Expert Committee,
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
Reducing risk in heart disease
Reducing risk in heart disease An expert guide to clinical practice for secondary prevention of coronary heart disease Prof Patricia Davidson (chair) Prof Nigel Stocks Dr Anu Aggarwal Ms Jill Waddell Ms
Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
ACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?
2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra
NEW JERSEY 2011 HOSPITAL PERFORMANCE REPORT TECHNICAL REPORT: METHODOLOGY RECOMMENDED CARE (PROCESS OF CARE) MEASURES
NEW JERSEY 2011 HOSPITAL PERFORMANCE REPORT TECHNICAL REPORT: METHODOLOGY RECOMMENDED CARE (PROCESS OF CARE) MEASURES New Jersey Department of Health and Senior Services Health Care Quality Assessment
NEW JERSEY 2012 HOSPITAL PERFORMANCE REPORT TECHNICAL REPORT: METHODOLOGY RECOMMENDED CARE (PROCESS OF CARE) MEASURES
NEW JERSEY 2012 HOSPITAL PERFORMANCE REPORT TECHNICAL REPORT: METHODOLOGY RECOMMENDED CARE (PROCESS OF CARE) MEASURES New Jersey Department of Health Health Care Quality Assessment June 2013 NEW JERSEY
Prevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
Ischemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
Maryland Patient Safety Center s Annual MEDSAFE Conference: Taking Charge of Your Medication Safety Challenges November 3, 2011 The Conference Center
Maryland Patient Safety Center s Annual MEDSAFE Conference: Taking Charge of Your Medication Safety Challenges November 3, 2011 The Conference Center at the Maritime Institute Pharmacy-Driven Inpatient
Heparin-Induced Thrombocytopenia. Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital
Heparin-Induced Thrombocytopenia Steven Baroletti, PharmD., M.B.A., BCPS Brigham and Women s Hospital Heparin-induced thrombocytopenia (HIT) A serious concern associated with thrombosis development following
Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules
Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Jane Vo, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
Reducing 30-day Rehospitalization for Heart Failure: An Attainable Goal?
Reducing 30-day Rehospitalization for Heart Failure: An Attainable Goal? Ileana L. Piña, MD, MPH Professor of Medicine, Epi/Biostats Case Western Reserve University Graduate VA Quality Scholar Cleveland
University of Wisconsin - Madison Cardiovascular Medicine Fellowship Program UW CICU Rotation Goals and Objectives
Background: The field of critical care cardiology has evolved considerably over the past 2 decades. Contemporary critical care cardiology is increasingly focused on the management of patients with advanced
University of Toronto Rotation Specific Objectives. cardiac rehabilitation
University of Toronto Rotation Specific Objectives Cardiac Rehabilitation For this rotation, please FOCUS the evaluation on the following CanMEDs roles: 1) Medical Expert; 2) Collaborator; 3) Health Advocate
Scottish Medicines Consortium
Scottish Medicines Consortium valsartan 40mg, 80mg and 160mg capsules and tablets (Diovan ) No. (162/05) Novartis Pharmaceuticals New Indication: following myocardial infarction in patients with clinical